Skip to main content
SpringerLink
Log in

Impact of Lymph Node Sampling in Stage II and III Epithelial Ovarian Cancer Patients with Clinically Negative Lymph Nodes

  • Original Article
  • Published:
Indian Journal of Surgical Oncology Aims and scope Submit manuscript

Abstract

The main surgical treatment of stage II and III epithelial ovarian cancer (EOC) is complete cytoreduction, while the main role of lymph node sampling is to exclude microscopic stage III disease in an apparent stage I EOC. This study aims to evaluate the impact of lymph node sampling in stage II and III EOC patients with clinically negative lymph nodes. This is a retrospective cohort study including 51 stage II and III EOC patients treated and followed up between 2012 and 2016. They were treated by complete cytoreduction. Sixteen cases had lymph node sampling, while it was not done in 35 cases. The study was performed at National Cancer Institute (NCI)-Cairo University. There was no statistically significant difference regarding overall survival (P value 0.649) or disease-free survival (P value 0.372) between the group of patients who had lymph node sampling and the other group of patients who had no lymph node sampling. Lymph node ratio (LNR) was not associated with a statistically significant impact regarding overall survival or disease-free survival. There is no impact of lymph node sampling on stage II and III EOC patients with clinically negative lymph nodes.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Siegel RL, Miller KD, Jemal A (2015) Cancer statistics, 2015. CA Cancer J Clin 65(1):5–29. https://doi.org/10.3322/caac.21254

    PubMed  Google Scholar 

  2. Dell’ Anna T, Signorelli M, Benedetti-Panici P, Maggioni A, Fossati R, Fruscio R, et al. Systematic lymphadenectomy in ovarian cancer at second-look surgery: a randomised clinical trial. Br J Cancer 2012; 107(5):785–792. https://doi.org/10.1038/bjc.2012.336

    PubMed  PubMed Central  Google Scholar 

  3. Mikami M (2014) Role of lymphadenectomy for ovarian cancer. J Gynecol Oncol 25(4):279–281. https://doi.org/10.3802/jgo.2014.25.4.279

    CAS  PubMed  PubMed Central  Google Scholar 

  4. Wu SG, He ZY, Li Q, Sun JY, Li FY, Lin Q, Lin HX, Guan XX (2013) Prognostic value of metastatic axillary lymph node ratio for Chinese breast cancer patients. PLoS One 8(4):e61410. https://doi.org/10.1371/journal.pone.0061410

    CAS  PubMed  PubMed Central  Google Scholar 

  5. Wei C, Deng WY, Li N, Shen W, Zhang C, Liu JY, Luo SX (2015) Lymph node ratio as an alternative to the number of metastatic lymph nodes for the prediction of esophageal carcinoma patient survival. Dig Dis Sci 60(9):2771–2776. https://doi.org/10.1007/s10620-015-3681-1

    PubMed  Google Scholar 

  6. Melis M, Masi A, Pinna A, Cohen S, Hatzaras I, Berman R, Pachter LH, Newman E (2015) Does lymph node ratio affect prognosis in gastroesophageal cancer? Am J Surg 210(3):443–450. https://doi.org/10.1016/j.amjsurg.2014.12.042

    PubMed  Google Scholar 

  7. Zekri J, Ahmad I, Fawzy E, Elkhodary TR, Al-Gahmi A, Hassouna A et al (2015) Lymph node ratio may predict relapse free survival and overall survival in patients with stage II & III colorectal carcinoma. Hepatogastroenterology. 62(138):291–294

    PubMed  Google Scholar 

  8. Fischer LK, Katz MH, Lee SM, Liu L, Wang H, Varadhachary GR, Wolff RA, Lee JE, Maitra A, Roland CL, Fleming JB, Estrella J, Rashid A, Wang H (2016) The number and ratio of positive lymph nodes affect pancreatic cancer patient survival after neoadjuvant therapy and pancreaticoduodenectomy. Histopathology. 68:210–220. https://doi.org/10.1111/his.12732

    PubMed  Google Scholar 

  9. Morice P, Joulie F, Camatte S, Atallah D, Rouzier R, Pautier P et al (2003) Lymph node involvement in epithelial ovarian cancer: analysis of 276 pelvic and paraaortic lymphadenectomies and surgical implications. J Am Coll Surg 197(2):198–205

    PubMed  Google Scholar 

  10. Harter P, Gnauert K, Hils R, Lehmann TG, Fisseler-Eckhoff A, Traut A, du Bois A (2007) Pattern and clinical predictors of lymph node metastases in epithelial ovarian cancer. Int J Gynecol Cancer 17(6):1238–1244. https://doi.org/10.1111/j.1525-1438.2007.00931.x

    CAS  PubMed  Google Scholar 

  11. Maggioni A, Benedetti Panici P, Dell’Anna T et al (2006) Randomised study of systematic lymphadenectomy in patients with epithelial ovarian cancer macroscopically confined to the pelvis. Br J Cancer 95(6):699–704

    CAS  PubMed  PubMed Central  Google Scholar 

  12. Panici PB, Maggioni A, Hacker N, Landoni F, Ackermann S, Campagnutta E, Tamussino K, Winter R, Pellegrino A, Greggi S, Angioli R, Manci N, Scambia G, Dell'Anna T, Fossati R, Floriani I, Rossi RS, Grassi R, Favalli G, Raspagliesi F, Giannarelli D, Martella L, Mangioni C (2005) Systematic aortic and pelvic lymphadenectomy versus resection of bulky nodes only in optimally debulked advanced ovarian cancer: a randomized clinical trial. J Natl Cancer Inst 97(8):560–566

    PubMed  Google Scholar 

  13. du Bois A, Reuss A, Harter P, Pujade-Lauraine E, Ray-Coquard I, Pfisterer J, Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom, Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (2010) Potential role of lymphadenectomy in advanced ovarian cancer: a combined exploratory analysis of three prospectively randomized phase III multicenter trials. J Clin Oncol 28(10):1733–1739. https://doi.org/10.1200/JCO.2009.25.3617

    PubMed  Google Scholar 

  14. Eoh KJ, Lee JY, Yoon JW et al (2017) Role of systematic lymphadenectomy as part of primary debulking surgery for optimally cytoreduced advanced ovarian cancer: Reappraisal in the era of radical surgery. Oncotarget 8(23):37807–37816. https://doi.org/10.18632/oncotarget.13696

    PubMed  Google Scholar 

  15. Ataseven B, Grimm C, Harter P, Prader S, Traut A, Heitz F, du Bois A (2014) Prognostic value of lymph node ratio in patients with advanced epithelial ovarian cancer. Gynecol Oncol 135(3):435–440. https://doi.org/10.1016/j.ygyno.2014.10.003

    PubMed  Google Scholar 

  16. Bachmann C, Brucker SY, Kraemer B, Rothmund R, Staebler A, Fend F, Wallwiener D, Grischke EM (2015) The prognostic relevance of node metastases in optimally cytoreduced advanced ovarian cancer. J Cancer Res Clin Oncol 141(8):1475–1480. https://doi.org/10.1007/s00432-015-1945-y

    CAS  PubMed  Google Scholar 

  17. Zhou J, He ZY, Li FY et al (2016) Prognostic value of lymph node ratio in stage IIIC epithelial ovarian cancer with node-positive in a SEER population-based study. Oncotarget 7(7):7952–7959. https://doi.org/10.18632/oncotarget.6911

    PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgments

The study was supported by NCI - Cairo University.

Author information

Authors and Affiliations

  1. Surgical Oncology Department, National Cancer Institute-Cairo University, 1 Kasr El- Aini Street, Foum El- Khalig, Cairo, 11796, Egypt

    Mohamed Ibrahim Fahim & Abdelmaksoud Mohamed Ali

  2. Biostatistics & Cancer Epidemiology Department, National Cancer Institute-Cairo University, 1 Kasr El- Aini Street, Foum El- Khalig, Cairo, 11796, Egypt

    Rasha Mahmoud Allam

Authors
  1. Mohamed Ibrahim Fahim
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Abdelmaksoud Mohamed Ali
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Rasha Mahmoud Allam
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mohamed Ibrahim Fahim.

Ethics declarations

All of the patients included in the study signed informed consents. The study was approved by the ethical committee of the National Cancer Institute. Clinical data of the patients were collected from hospital records, recorded in a standard database form, and evaluated and analyzed by the authors.

NCI played no role in the study design, data collection, data analysis, or manuscript writing. All authors read and approved the final manuscript.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Fahim, M.I., Ali, A.M. & Allam, R.M. Impact of Lymph Node Sampling in Stage II and III Epithelial Ovarian Cancer Patients with Clinically Negative Lymph Nodes. Indian J Surg Oncol 11, 196–200 (2020). https://doi.org/10.1007/s13193-019-01013-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13193-019-01013-5

Keywords

Search

Navigation